Home > Pulmonology > NLC 2022 > Challenges in Upper Airway Diseases > CRSwNP outlined

CRSwNP outlined

Presented by
Dr Sanna Toppila-Salmi, University of Helsinki, Finland
NLC 2022
Chronic rhinosinusitis with nasal polyps (CRSwNP) and non-steroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (NERD) occur more often than previously assumed. A lack of knowledge as well as limited nasal endoscopy facilities/access are likely explanations for the underdiagnosis of both conditions in the general population.

CRS – with or without nasal polyps – is defined as the presence of two or more symptoms lasting for over 12 weeks, i.e. obstruction OR drainage +/- loss of smell, facial pain/pressure AND endoscopic polyps/mucus/oedema OR mucosal change on CT sinus scans [1]. The estimated prevalence of chronic rhinosinusitis without nasal polyps (CRSsNP) is 90/1000 individuals, for asthma: 100/1000 and for CRSwNP: >10/1000; NERD has a prevalence of <10/1000 . It needs to be noted that accurate diagnostics are often lacking [1,2]. “Therefore, the true number may be higher,” Dr Sanna Toppila-Salmi (University of Helsinki, Finland) explained. “CRSwNP, NERD, and CRSsNP are chronic recurrent conditions and in patients with concomitant lower airway involvement all associate with uncontrolled disease and, hence, impose a substantial burden on health care resources,” Dr Toppila-Salmi explained [2–5].

  1. Fokkens WJ, et al. Rhinology. 2020 Apr 1;58(2):82-111.
  2. Toppila-Salmi S, et al. BMC Pulmon Med. 2021;214(21).
  3. Pentillä E, et al. Asian Pac J Allergy Immunol. 2021 Sep 5. doi: 10.12932/AP-310321-1102.
  4. Lilja M et al. Allergy Rhinol (Providence). 2021 Apr 26;12:21526567211003844.
  5. Toppila-Salmi S. Prevalence and predictive factors for CRSwNP and ASA-intolerance. Nordic Lung Congress 2022, 01–03 June, Copenhagen, Denmark.


Copyright ©2022 Medicom Medical Publishers

Posted on